Biotechnology
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, July 5, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced...
2023-07-05 23:07
2652
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company, today announced the appointment ofFurqan Ahmed, PharmD., as the Vice President and Head of Business Development. In this position, Furqan will be responsible fo...
2023-07-05 22:05
2084
TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
- Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagonist inChina - TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis inEurope by the end of the year BOSTON and SEONGNAM, South Korea, July 5, 2023 /P...
2023-07-05 20:00
2230
BGI CEO Yin Ye Advocates for Global Technology Sharing
SHENZHEN, China, July 5, 2023 /PRNewswire/ -- Speaking on a panel at the 10th Arab-China Business Conference inRiyadh, Saudi Arabia, Dr Yin Ye, BGI Group CEO, reinforced the importance of making technological advancements available to everyone through scientific sharing to benefit humanity. "We ...
2023-07-05 14:17
1850
Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China
BEIJING, SHANGHAI and BOSTON, July 4, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its novel KRAS G12C inhibitor glecirasib's pivotal study for pancreatic cancer has been approved from CDE (Center for Drug Evalu...
2023-07-04 21:16
2361
Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer
Highlights * FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer * Phase III trial design based on 64Cu SAR-bisPSMA data package, including positive results from the completed PROPELLER trial * A total of 383 prostate cancer patients to take part ...
2023-07-04 20:55
2372
China NMPA approves RareStone's pitolisant (Wakix) for the treatment of narcolepsy
-- pitolisant is the first and only treatment drug approved in mainland China for narcolepsy. SHANGHAI, July 4, 2023 /PRNewswire/ -- RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chinese National Med...
2023-07-04 20:42
1966
PETCUBES INTRODUCES GROUNDBREAKING 'VETERINARY SUPPORT DIET' RANGE FOR DOGS WITH SPECIAL HEALTH NEEDS
* Revolutionary Range Of Nutrient-Rich Meals Trialled In Collaboration With Temasek Polytechnic, Designed To Support Unique Nutritional Requirements Of Pets With Specific Health Conditions * Veterinary Support Diet Range is Gently Cooked, which effectively kills any possible contaminants whil...
2023-07-04 14:00
2202
AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
BRIDGEWATER, N.J. and BENGALURU, India, July 3, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab), is now available to patients inthe United States after five years of experien...
2023-07-04 01:22
2391
Lumos Receives US FDA Clearance for FebriDx®
MELBOURNE, Australia, July 3, 2023 /PRNewswire/ -- Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® r...
2023-07-03 21:50
2625
Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
SHANGHAI and BOSTON, July 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...
2023-07-03 19:00
1659
Henlius Forecasts Profit in 1H 2023
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...
2023-07-03 18:59
4482
Henlius Forecasts Profit in 1H 2023
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...
2023-07-03 17:49
2356
Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease
SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health ...
2023-07-03 08:00
2835
Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
ROCKVILLE, Md. and SUZHOU, China, July 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-07-03 08:00
4334
Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing
* Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based inRiyadh. * JV focuses on providing state-of-the-art multiomic testing services to patients, health system...
2023-07-02 14:00
3295
Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023
* 64 patients with CLDN18.2 positive G/GEJ cancer were enrolled in TranStar102 (TST001-1002). CLDN18.2 positivity is defined as ≥10% tumor cells with ≥1+ intensity. These patients represent approximately 55% of all G/GEJ adenocarcinomas. The overall median PFS was 9.5 months with no differences...
2023-06-30 17:33
2791
BGI Genomics obtains BSI ISO 37301 Compliance Management System Certification
HONG KONG, June 30, 2023 /PRNewswire/ -- As businesses become increasingly global, changes are happening at an extraordinary pace. Compliance is critical for large economies, industry regulations, and enterprise operations. BGI Genomics prioritizes compliance management and strictly follows law...
2023-06-30 08:37
3020
Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology
NEW YORK, June 29, 2023 /PRNewswire/ -- Cresilon, Inc. ("Cresilon"), a Brooklyn -based biotechnology company focused on hemostatic medical device technologies, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ...
2023-06-29 20:00
2125
Angel Yeast Partners with PhaBuilder to Drive Wider Synthetic Biology Applications with Launch of Joint Venture PHA Factory
YICHANG, China, June 29, 2023 /PRNewswire/ -- Angel Yeast
2023-06-29 20:00
3275
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 295 media titles]
2024-11-28 17:24TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
12035
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
8090
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
7831
MMA SMARTIES Thailand 2024 - Celebrates Unparalleled Marketing Innovation and Excellence in Thailand
2024-11-23 11:00
7248
WeBank Powers Fusion Bank's Rapid Launch of a Next-Generation Core Banking System
2024-11-22 15:21
5581